AIM Vaccine Co., Ltd.

AIM Vaccine Co., Ltd. engages in the research and development, manufacturing, and commercialization of vaccine products for human use in the People's Republic of China. The company's product pipeline includes Bivalent Delta-Omicron BA.5 mRNA and Monovalent Omicron BA.5 mRNA, which is in phase III clinical trails for the treatment of COVID-19; EV71-CA16 Bivalent for HFMD; and Valent Pneumococcal Conjugate and Polysaccharide vaccine for pneumococcal disease. It also offers Hexavalent group B Streptococcus Polysaccharide Conjugate Vaccine for Group B strep disease; Diphtheria, Tetanus and Pertussis and Haemophilus In¬uenzae type B, and Diphtheria, Tetanus and Acellular Pertussis, and Absorbed Tetanus for DTP; Haemophilus In¬uenzae Type B for Hib; and freeze-dried human rabies and mRNA human rabies vaccine. In addition, the company develops Human Papillomavirus 2 and 3-valent vaccine; Tetravalent Meningococcal Conjugate vaccine; Tetravalent In¬uenzae vaccine; mRNA Shingles/Herpes Zoster vaccine; mRNA respiratory syncytial virus vaccine; live attenuated parotitis vaccine; and ACYW135 meningococcal polysaccharide vaccine. The company was formerly known as Beijing AIM Biological Vaccine Technology Group Co., Ltd. and changed its name to AIM Vaccine Co., Ltd. in September 2020. AIM Vaccine Co., Ltd. was incorporated in 2011 and is headquartered in Beijing, the People's Republic of China.